Project Grant R15CA293800
Award Date
7/15/24
Completion Date
6/30/27
Dollars Obligated
$434K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Provo, UT 84602, USA
Similar Awards
This $432,304 federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), supports a research project titled "Enhanced Cancer Risk Predictions in Underrepresented Populations through Robust Multi-Source Data Integration." The project aims to develop novel data integration methods to enhance cancer risk prediction models, particularly for Black and Hispanic populations who face disproportionate cancer...
This $2,372,456 federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports a multi-institutional research collaboration led by Memorial Sloan Kettering Cancer Center to leverage observational (real-world) data to advance precision oncology. The key products/services to be delivered include: Overcoming methodological barriers in analyzing observational clinico-genomic data (Project 1) Addressing the role of...
The National Cancer Institute (NCI) awarded a $455,111 Project Grant under CFDA 93.393 "Cancer Cause and Prevention Research" to the Sloan-Kettering Institute for Cancer Research in New York. The 2-year grant, awarded on September 5, 2023, will support research to "Leverage the Hidden Genome to Recover the Missing Heritability of Cancer." The project aims to 1) estimate additional heritability that can be explained by the "hidden genome" (regions of unknown...
This $585,931 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) will support research by the University of Pittsburgh to develop a comprehensive framework for evaluating the molecular congruence and selection of cancer models, such as cell lines, patient-derived xenografts (PDX), and patient-derived organoids (PDO), to guide translational and clinical applications. The research aims to: (1) identify and clinically annotate...
This $505,613 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development of statistical and computational approaches to leverage genomic data for precision cancer prevention and risk stratification. The key objectives are to: (1) create deep learning-based methods that combine unsupervised and supervised techniques to identify tumor subtypes linked to poor outcomes, while integrating external...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $150,271 to the University of Maryland Baltimore County (UMBC) to investigate the role of the protein kinase ADCK5 in ovarian cancer. The 2-year project, which began on September 20, 2023, aims to gain fundamental insights into the mechanisms underlying ovarian cancer, the most lethal gynecologic malignancy in the United States. The research seeks to identify potential new...
This $1,104,864 Project Grant awarded by the National Cancer Institute (CFDA 93.396 Cancer Biology Research) supports research at the University of California, Davis to understand the molecular mechanisms of homologous recombination (HR) and how defects in recombinational DNA repair can lead to chromosomal instability and cancer predisposition. The key objectives are to elucidate the functions of BRCA2 protein and the RAD51 paralogs in mediating and potentiating homologous DNA pairing by...
This $1,354,931 federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to The University of Texas Southwestern Medical Center aims to develop a framework of principles to provide practical guidance on variant reinterpretation, reclassification, and recontact in medical genetics. The project involves qualitative research including focus groups, deliberations, and a Delphi panel with six stakeholder groups to identify underlying...
This Project Grant award, with funding of $642,394.00, was provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program. The grant supports research investigating the impact of deoxyuridine (DU) contamination on innate immune responses in cancer cells treated with chemotherapies and radiation. The key objectives are to: 1) identify pattern recognition receptors that do not recognize DNA fragments when thymidine is replaced...
This $432,614 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program supports research at Duke University to investigate the relationship between chromosomal instability, loss of chromosome 17p, and dependence on the mitotic regulator NDE1 in cancer cells. The research aims to characterize how these genetic alterations contribute to vulnerabilities that could be therapeutically targeted. Specifically, the project will define the link...